May 26th, 2010 by DrWes in Better Health Network, Health Policy, Opinion, Research
1 Comment »
“…I have always depended on the kindness of strangers.” — Blanche DuBois in Tennessee Williams’ play A Streetcar Named Desire
Years ago when I began my medical training, I recall enrolling patients for clinical research. In cardiology, there were a myriad of questions that needed to be answered, especially in the area of defining which medications were best to limit the damage caused by a heart attack.
Patients routinely participated in large, multi-center prospective randomized trials to answer these questions. It was routine for them not to charged for participating in the trial — the drug(s) and additional testing would be funded by the company whose drug was being studied. Patients enrolled willingly, eager to help advance science and perhaps, in some small way, their fellow man. It never dawned on me in those early days why hospitals and research centers were so eager to promote research. Read more »
*This blog post was originally published at Dr. Wes*
May 24th, 2010 by DrWes in Better Health Network, Health Policy, Opinion, True Stories
No Comments »
Doctors are all-familiar with marketing efforts to promote new drugs, but once the new drugs displace older drugs in the medical marketplace, who serves as advocates for the continued manufacturing of older FDA-approved drugs?
In a short answer: No one.
For those of us dealing in cardiac arrhythmia management, this presents difficult challenges for patient care if people are unable to take the newer drugs due to side effects. These patients no longer have a fall-back option to turn to for medical therapy when the older drugs have become extinct on the marketplace. Read more »
*This blog post was originally published at Dr. Wes*
April 29th, 2010 by Steve Novella, M.D. in Better Health Network, Health Policy, Opinion, Research
1 Comment »
To be blunt up front –- SBM is not apologetic about the pharmaceutical industry. We get zero funding from any company, and have no ties of any kind to “big pharma.” In today’s world I have to spend time making that clear, because despite the reality critics are free to assume and falsely claim that our message is coming straight from the bowels of hell (a.k.a. the pharmaceutical industry).
We promote science-based medicine and criticize pharmaceutical companies along with everyone else when they place other concerns ahead of scientific validity, or promote bad science, for whatever reason.
It has become fashionable, however, to not only criticize the pharmaceutical industry but to demonize them –- and the term “big pharma” has come to represent this demonization. Cynicism is a cheap imitation of skepticism –- it is the assumption of the worst, without careful thought or any hint of fairness. Read more »
*This blog post was originally published at Science-Based Medicine*
April 15th, 2010 by RamonaBatesMD in Better Health Network, Health Policy, News, Opinion, Research
No Comments »
The Washington Post had a story by Lyndsey Layton this past week: FDA says studies on triclosan, used in sanitizers and soaps, raise concerns. An excerpt:
The Food and Drug Administration said recent research raises “valid concerns” about the possible health effects of triclosan, an antibacterial chemical found in a growing number of liquid soaps, hand sanitizers, dishwashing liquids, shaving gels and even socks, workout clothes and toys.
The FDA and the Environmental Protection Agency say they are taking a fresh look at triclosan, which is so ubiquitous that is found in the urine of 75 percent of the population, according to the Centers for Disease Control and Prevention. The reassessment is the latest signal that the Obama administration is willing to reevaluate the possible health impacts of chemicals that have been in widespread use.
No where in the article is the use of triclosan use in suture mentioned, yet in my research on allergy/reactivity to suture material I found that it is. Read more »
*This blog post was originally published at Suture for a Living*
March 28th, 2010 by PhilBaumannRN in Better Health Network, Opinion
No Comments »
There’s been an ongoing discussion about how the Life Sciences industries can face and integrate recently-evolving media which the Web has been and continues to sprout. Remarkable as they are, the discussions are endless and most loop back into themselves without generating sufficient voltage to power an army of macrophages. Additionally, pharmaceutical companies (pharma) –- beset by a myriad of constraints –- are anxious about flipping on social connection switches which the Web furiously creates every day. We could say that pharma has a sort of social media anxiety disorder. What to do?
The answer isn’t in social media. It’s not in what the FDA decides to do. It’s not in echo chambers found within Twitter or blogs or conferences. It lies in simple, basic economic truths. It lies in radical acceptance and in brave recreation. It lies beneath the proverbial nose of obviousness. It lies far beyond any discussion about the meanings and promises and purposes of new media on the Web. Pharma’s social media anxiety disorder is merely a peripheral symptom of deeper pathologies. Let’s assess the patient. Read more »
*This blog post was originally published at Phil Baumann*
